

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 May 2001 (25.05.2001)

PCT

(10) International Publication Number
WO 01/36401 A1

(51) International Patent Classification⁷: **C07D 277/34**,
A61K 31/425

W.; 615 South 7th Street, Lafayette, IN 47905 (US). **RUSSELL, Catherine**; 2018 Winflower Place, West Lafayette, IN 47906 (US).

(21) International Application Number: PCT/US00/31705

(22) International Filing Date:
17 November 2000 (17.11.2000)

(74) Agents: **JOHNSON, Philip, S.** et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/166,515 19 November 1999 (19.11.1999) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.


(71) Applicant: **ORTHO-MCNEIL PHARMACEUTICAL, INC.** [US/US]; U.S. Route #202, P.O. Box 300, Raritan, NJ 08869-0602 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors: **ANDRES, Mark, C.**; 1315 El Prado Road, Lafayette, IN 47905 (US). **BRYN, Stephen, R.**; 824 Barrow Street, Lafayette, IN 47906 (US). **NEWMAN, Ann**,

[Continued on next page]

(54) Title: SOLID STATE FORMS OF 5-[[6-[(2-FLUOROPHENYL)METHOXY]-2-NAPHTHALENYL]METHYL]-2,4-THIAZOLIDINEDIONE



(57) Abstract: The present invention provides a crystal form, termed E type crystal form, and an amorphous form of 5-[[6-[(2-fluorophenyl)methoxy]-2-naphthalenyl]methyl]-2,4-Thiazolidinedione (MCC-555) that are distinguishable from known crystal forms. The present invention also provides a method for preparation thereof and pharmaceutical compositions comprising the E type crystal form, or amorphous forms of MCC-555.



WO 01/36401 A1



Published:

— *With international search report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.